A pre-treatment pill may supercharge cancer-fighting immune cells

NCT ID NCT07727668

Not yet recruiting Disease control Sponsor: Shambavi Richard Source: ClinicalTrials.gov ↗

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This early-phase trial tests whether giving the drug iberdomide before collecting a patient's T cells can improve the fitness of those cells for CAR-T therapy. The study enrolls adults with relapsed or refractory multiple myeloma who are already scheduled for standard CAR-T treatment. Researchers will measure changes in T cell subtypes and look for signs of better immune cell expansion after the CAR-T infusion.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: iberdomide (CC-220) capsules taken by mouth before standard CAR-T therapy
What this could lead to: If it works, this approach could make CAR-T therapy more effective for people with hard-to-treat multiple myeloma.
What could go wrong: This is a very early, small feasibility study, so it may not show clear benefit. Iberdomide can cause side effects like fatigue, low blood counts, and infection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA RELAPSED/REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Locations

Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.